Abstract:Abstract Background: BET inhibitors (BETi) exhibit a strong anti-tumor activity in triple-negative breast cancer (TNBC). However, BETi resistance has been reported in TNBC. The mechanisms of resistance have not been demonstrated. Tumor-associated macrophages (TAMs) are frequently involved in cancer cells resistance to chemotherapy, also associated with poor prognosis in TNBC. However, the role of TAMs in BETi resistance remains unknown. Method: The expression of RNA was evaluated by qRT-PCR. Protein was detected by Western blot, immunofluorescence and Enzyme linked immunosorbent assay (ELISA). Cell viability was detected by Cell Counting Kit-8 (CCK-8). Apoptosis was evaluated by Annexin V-FITC/PI, TUNEL assays and Hoechst 33258 staining. NF-κB activities were detected by luciferase reporter assays. Mice model of breast cancer was established with subcutaneous xenograft tumor. Detailed mechanistic studies were performed by using inhibitors, RNA interference and DNA transfections. Results: Here, we found that BETi JQ1 and I-BET151 exerted anti-tumor effects in TNBC by decreasing IKBKE expression to attenuate NF-κB signaling. BET inhibition was found to downregulate IKBKE levels through BRD2/E2F1 axis. Moreover, we firstly found that TNBC-stimulated TAMs activated NF-κB signaling by upregulating IKBKE expression to enhance breast cancer cells resistance to BETi. The IKBKE levels were also proved to be higher in clinical TNBC tissues than Non-TNBC tissues, suggesting feedback induction of IKBKE expression by TNBC-stimulated TAMs in TNBC. In addition, the induction of IKBKE by TAMs in TNBC cells was identified to be associated with STAT3 signaling, which was activated by TAM-secreted IL-6 and IL-10. Lastly, the combination of inhibitors of BET and STAT3 exerted a synergistic inhibition effects in TAM-cocultured or TAM CM-treated TNBC cells in vitro and in vivo . Conclusion: Altogether, our findings illustrated TNBC-activated macrophages conferred TNBC cells resistance to BETi via IL-6 or IL-10/STAT3/IKBKE/NF-κB axis. Blockade of IKBKE or double inhibition of BET and STAT3 might be a novel strategy for treatment of TNBC.

IKBKE is Induced by STAT3 and Tobacco Carcinogen and Determines Chemosensitivity in Non-Small Cell Lung Cancer.

Abstract 3255: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

Abstract 4991: Upregulation and the role of IKBKE in non-small cell lung cancer

Nicotine Enhances Invasion and Metastasis of Human Colorectal Cancer Cells Through the Nicotinic Acetylcholine Receptor Downstream P38 MAPK Signaling Pathway.

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Reciprocal Activation of Α5-Nachr and STAT3 in Nicotine-Induced Human Lung Cancer Cell Proliferation.

Stat3 Downstream Genes Serve As Biomarkers in Human Lung Carcinomas and Chronic Obstructive Pulmonary Disease.

Inflection of Akt/mTOR/STAT-3 cascade in TNF-α induced protein 8 mediated human lung carcinogenesis

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC

LKB1 Phosphorylation and Deactivation in Lung Cancer by NNAL, a Metabolite of Tobacco-Specific Carcinogen, in an Isomer-Dependent Manner

Abstract 4173: IKBKE/IKKα is a prognostic marker and is required for KRAS-driven tumorigenecity in non-small cell lung cancer

STAT3 Activation Inhibits Human Bronchial Epithelial Cell Apoptosis in Response to Cigarette Smoke Exposure

IKBKE, a Prognostic Factor Preferentially Expressed in Mesenchymal Glioblastoma, Modulates Tumoral Immunosuppression Through the STAT3/PD‐L1 Pathway

SUMOylation and SENP3 Regulate STAT3 Activation in Head and Neck Cancer

Akt/PKB Signaling Regulates Cigarette Smoke-Induced Pulmonary Epithelial-Mesenchymal Transition.

EGFR-AS1/HIF2A Regulates the Expression of FOXP3 to Impact the Cancer Stemness of Smoking-Related Non-Small Cell Lung Cancer

IKBKE is a critical mediator of TAM-induced breast cancer resistance to BET inhibition

NNAL, a major metabolite of tobacco-specific carcinogen NNK, promotes lung cancer progression through deactivating LKB1 in an isomer-dependent manner

SphK1 Promotes Development of Non‑small Cell Lung Cancer Through Activation of STAT3.

Nicotine Promotes the Development of Non-Small Cell Lung Cancer Through Activating LINC00460 and PI3K/Akt Signaling